Synopsis:
Pharma company’s shares are in focus after its promoter Karuna Business Solutions LLP acquired a 0.17 percent stake worth about Rs. 34.7 crore through a block deal.
A Small-cap company that is in the research, development, manufacture and commercialisation of biological drug products in various injectable formats, is in the spotlight today after its promoter increased 0.17 percent stake in the company through a block deal on November 17, 2025.
With a market capitalization of Rs. 19,878.82 crore, OneSource Specialty Pharma Ltd is trading at Rs. 1,739.70, down by 2.71 percent from its previous close of Rs. 1,788.20 per equity share. The shares touched an intraday low of Rs. 1,701.50 in today’s trading session. As of September, 2025, an ace investor Mukul Mahavir Agarwal holds 1.05 percent stake in the company.
What’s the deal?
According to the latest block deal data on the NSE, promoter Karuna Business Solutions LLP acquired 2 lakh shares at an average price of Rs. 1,735 from Amansa Holdings private Ltd, totaling approximately Rs. 34.7 crore and representing a 0.17 percent stake.
As of September 2025, Karuna Business Solutions LLP holds a 6.89 percent stake in the company, while Amansa Holdings private Ltd holds 3.45 percent stake in the company.
About the company
OneSource Specialty Pharma Limited, formerly Stelis Biopharma Limited, is a Bengaluru-based biopharmaceutical company founded in 2007 that operates across India, Ireland, the United States, and other international markets. It focuses on researching, developing, manufacturing, and commercializing biological drug products in injectable formats, while offering end-to-end CDMO services from preclinical and clinical development to commercial biologics supply.
The company also provides drug-device combinations such as prefilled syringes and various pen injectors, autoinjectors, sterile injectables, soft-gel capsules, and biologics solutions spanning microbial and mammalian platforms, as well as cell and gene therapy and RNA products.
It is trading at a price-to-earnings (P/E) ratio of 144x, which is higher than the industry average of 31.6x. A return on equity (ROE) of about 3.34 percent and a return on capital employed (ROCE) of about 5.52 percent and debt to equity at 0.22 demonstrate the company’s financial position.
The company posted revenue of Rs. 375.76 crore in Q2FY26, up 12.5 percent YoY from Rs. 334.05 crore and 14.8 percent QoQ from Rs. 327.27 crore, while profit improved sharply to Rs. 10.49 crore, marking a full turnaround from losses of Rs. 0.19 crore in Q2FY25 and loss of Rs. 42.08 crore in Q1FY26, reflecting strong operational recovery and sustained sequential growth.
Written by Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
